Whether these variants were of functional relevance in these sisters remains an open question, but this study raises the interesting prospect that NGS strategies could potentially unmask genetic modifiers of phenotypic severity in MECP2 mutation-positive RTT patients, which could in turn point to potential novel therapeutic targets. This evidence concerns the gene MECP2 and Rett syndrome.